By Chandranath Chakraborty, Founder & Managing Partner · [email protected]
As tariffs redraw active ingredient economics across the region, the constraint that decides price sits in the regulatory filing, not the trade policy.
Pharmaceutical input costs are moving in unexpected directions. United States tariffs aimed at China have made Chinese penicillin ingredients cheaper worldwide. Sandoz's half-year results carry the footnote: the price fall took a percentage point off group sales growth. Section 232 duties on patented pharmaceuticals took effect on 31 July, doubling the landed cost of affected imports from most origins. Generics are excluded, and the heaviest rate lands on Europe, the source of almost half of America's active ingredient imports by value.
These are not the effects the policy describes. The duty barely touches the country it names, presses hardest on the largest supplying region, and has already cut prices in the excluded segment.
The sourcing decision, however, is not made in the tariff schedule.
For a company buying pharmaceutical inputs, the price outcome was fixed years before the tariff, in the regulatory filing that names which sites may supply each molecule. Until a second source is qualified, the price conversation has one supplier in it. Management needs to know how many qualified sources stand behind each molecule sold, which single-source molecules carry material spend and who holds that list.
MomentumX works from that fact base through qualification strategy, sourcing waves, negotiation, implementation and value delivery.
For the worked model behind this analysis, or to discuss a direct material estate: [email protected]
The measure itself is not in dispute. The Federal Register notice of 9 April 2026 sets a default duty of 100% on covered patented pharmaceuticals and their ingredients. A consignment invoiced at US$1 million clears at US$2 million landed. It took effect on 31 July for the companies listed in the proclamation and reaches all other importers from 29 September. The European Union and several allied economies carry 15%, the United Kingdom 10%. Generic medicines and biosimilars are excluded.
The Tax Foundation, reading 2024 import data, put the European Union at 47% of United States active ingredient imports by value and China at under 4% of pharmaceutical imports overall. The duty falls hardest on the source supplying almost half the ingredients and barely touches the country the policy names.
The reporting season complicated the picture further. Merck and Pfizer reported margins moving in different directions in the same fortnight, and in neither case was the stated cause the price of a purchased input. A tariff of this size arriving without a visible margin signature says the effects are being absorbed, restructured or passed through in ways the disclosures do not separate.
US Pharmacopeia's Medicine Supply Map counts active ingredient master files, the dossiers that record which site may supply what. India holds 48% of the stock. China filed 45% of the new dossiers in 2024, the first year in more than two decades that China filed more than India.
The trade statistics still show Europe. Value-weighted imports and qualified capacity are different quantities, measured at different points in time. A sourcing strategy read off the trade data is a strategy for where the supply base was, not where it is going.
A price that fell after the duty is not a saving the sourcing team produced. Chinese penicillin ingredients cheapened worldwide under a measure aimed at China, and Sandoz's results carry the fall as a percentage point off group sales growth. That movement was in the market before any negotiation began. Performance is the gap between the price paid and the movement of the market the molecule trades in.
The separation settles the budget conversation. Finance plans next year's standard cost on the policy path: the duty rate that applies from 29 September and the share of it the supply chain passes through. The sourcing target sits on top of that path. A blended number hides both. Two numbers held apart show, at year end, which one moved.
Pass-through is measurable from records already held. The landed-cost file shows the duty paid by origin. The purchase-price file shows what the supplier charged. Read together, they show how much of the 100% arrived in the price and how much the supplier absorbed.
For regulated materials the separation carries one more term, the qualification position. Two companies paying the same price for the same molecule sit in different positions where one holds a single qualified source and the other holds three. The count of qualified sources sets the speed. Three support a negotiation in the next sourcing wave. A single source waits on the filing calendar.
None of the published material answers the question a company actually has. How many qualified sources exist for each molecule it sells? That count is not in the trade data and not in the margin disclosures. Somebody has to go molecule by molecule and build it.
Across the category engines, regulated direct materials behave differently from every other direct category. The price lever does not open until the regulatory lever has been pulled, and the regulatory lever takes stability data, comparability work and a filing variation measured in months.
The organisational pattern compounds it. The qualification list sits with regulatory affairs and the spend sits with procurement. Both are accurate. The two are rarely read against each other, and the view that would settle where a negotiation is worth having is the one nobody holds.
Qualification work is therefore capital expenditure with a procurement return, and it is almost never appraised that way. A second source costs money and time before it saves anything, and the saving arrives through a negotiation that becomes possible rather than a price that falls by itself.
Take two buyers holding the same underlying chemistry. The first imports a patented finished medicine manufactured in Ireland. From 31 July, where the importer is named in the proclamation, the European Union rate applies and the landed cost carries the duty.
The second buys 6-aminopenicillanic acid from a Chinese supplier and makes generic antibiotics. Generics are excluded and no duty applies. The input price has fallen anyway, with tariffs elsewhere pushing Chinese volume onto the world market.
Neither effect is visible in a published margin. That is the case for doing the work at molecule level. The output is a two-column list: spend by molecule against qualified sources by molecule. Single-source molecules carrying material spend belong in a qualification programme with a filing date against them. Molecules with two or more sources belong in a sourcing wave and should be run properly there.
The worked file behind this piece is available on request: [email protected].
The duty schedule sizes what a filing is worth before any negotiation on the price itself. A consignment invoiced at US$1 million clears at US$2 million landed under the default 100% rate, and at US$1.15 million under the European Union's 15%. The difference between two qualified origins on that one consignment is US$850,000.
The United Kingdom's 10% sits between the two, and the same consignment clears at US$1.1 million from a British site. The ranking of qualified origins by landed cost is a table a company can hold today, one line per molecule, before any filing is begun.
The master-file record gives the programme its geography. India holds 48% of the stock of dossiers, and China filed 45% of the new ones in 2024. A programme qualifying a second source today chooses between the established base and the base being built. The two sit on different sides of the policy already in force, and the penicillin case shows how far their prices can move apart.
Concentration also sets the order of work. Single-source molecules with material spend go first, and among them the ones whose origin clears at the 100% rate go before the ones already clearing at 15%. A filing date against each one turns the duty gap into a negotiation that can be scheduled.
The two-column map prices the programme as well as ordering it. Spend by molecule gives the base the duty gap applies to, and the count of qualified sources says which part of that base can move this year.
Most large manufacturers can produce both columns from records they already hold, and putting them side by side is a few weeks of work rather than a project.
The map creates an action plan with two speeds. The qualification programme runs on the regulatory calendar, with filing dates, stability studies and the spend each filing protects stated as its budget case. The sourcing waves run on the commercial calendar, on the molecules where competition already exists.
The objection that qualification is slow and expensive is real, and it prices the alternative: staying single-sourced through a tariff cycle whose rates have already moved once this year.
MomentumX can take the work through the full cycle. It starts with the molecule map and the sizing of the exposure. It ends with the sourcing waves run and the value verified in the accounts.
For CFOs, the molecule map separates tariff exposure that must be absorbed or passed through from cost a programme can actually reach. It also puts a number on the concentration risk the accounts do not show.
For CPOs, it defines the part of the direct material base that should carry a savings expectation this year. The rest of the base has an honest answer, and it is a filing date.
For regulatory and operating leaders, it makes the filing calendar the sourcing calendar. In fact it always was.
For private-equity sponsors, single-source molecules are a valuation question as much as a cost question. The qualified base shifting to India and China puts the exposure squarely inside APAC portfolios.
The same logic runs through any regulated direct material, in food as in medical devices as in aerospace. The management challenge is constant. How many qualified sources stand behind each critical input, and what does it take to add one?
For the worked model behind this article, a Confidential Spend Review of a specific category or contract, or a discussion on an APAC cost programme: [email protected]
MomentumX works from opportunity identification through commercial strategy, negotiation, implementation and value delivery.
A Confidential Spend Review — a senior look at a single category or contract, on client data under a non-disclosure agreement or on an illustrative basis.
Or the Spend Exposure Index, a confidential self-assessment completed privately, with no data shared.
Written by Chandranath Chakraborty, Founder & Managing Partner, MomentumX Consulting. Two decades running procurement for The Walt Disney Company, Nike, Unilever and Procter & Gamble, with structural cost reductions above 12 per cent across a US$1B+ regional spend base in his most recent role. LinkedIn · [email protected]